Novare Pharmaceuticals launches in Boston
- This week, Novare, a biotech start-up, launches in Boston. Novare focuses on products that use Receptor for Hyaluronan Mediated Motility (RHAMM) technology to treat various conditions.
- RHAMM modulation is a tissue engineering breakthrough that may have useful applications for treating arthritis and other inflammatory conditions, as well as fibrotic diseases and even regeneration of cells after a mastectomy.
- The goal of the therapy is to help the body regenerate its own tissue.
Novare is an expansion of an existing company, ProGDerm, which is a subsidiary of Allied Minds—a company that focuses on aiding the transfer of discoveries made at universities and federal research institutions to the commercial market. Novare will continue on the work already started by ProGDerm.
The RHAMM technology is particularly promising, with potential applications in everything from treating idiopathic pulmonary fibrosis to healing keloid scars.